NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01377844,Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT01377844,,COMPLETED,"The purpose of the study is to evaluate the efficacy of EGT0001442 in lowering glycosylated Hemoglobin (HbA1c, A laboratory test to diagnose three months average of blood sugar)levels at 24th week from baseline, when compared to placebo group(no diabetic medication given). The secondary aim of the study is to evaluate the efficacy of EGT0001442 in lowering fasting blood glucose at the weeks 2 and 24 and comparing the results with placebo group. This study assess the efficacy of EGT0001442 based on the proportion of subjects who reach the American Diabetes Association (ADA) target of HbA1c of \< 7% in EGT0001442 group and comparison with placebo. The study also evaluates the effect of EGT0001442 on systolic, diastolic pressures, body weight and compare with the respective placebo groups.This study also assess the change from baseline in HbA1c overtime, from week 1 to week 96. Finally, to assess the safety of EGT0001442 in the Type 2 Diabetic patients (adult/maturity onset).",YES,Diabetes Mellitus,DRUG: EGT0001442|DRUG: Placebo,"Change From Baseline in Hemoglobin A1c at 24 Weeks, Changes from baseline in HbA1c in placebo and treatment group at end of 24 weeks treatment, Baseline and Week 24","Changes in Systolic and Diastolic Blood Pressure at Week 24, Changes from baseline in systolic and diastolic blood pressure in placebo and treatment group after 24 weeks of treatment, Baseline and Week 24|Changes in Body Weight at Week 24, Changes from baseline in body weight in placebo and treatment group after 24 weeks of treatment, Baseline and week 24|Change From Baseline in HbA1c Over 96 Weeks Time, Change from baseline in HbA1c level over 96 weeks in placebo and treatment group. The treatment group was treated with EGT0001442 for 24 weeks., Baseline and up to 96 weeks|Change From Baseline Over Time in Fasting Plasma Glucose (FPG), Changes from baseline in FPG in placebo and treatment group over 24 weeks of treatment, 24 weeks|Percentage of Subjects Achieving HbA1c <7%, The number and percentage of subjects achieving HbA1c response levels \<7% for the FAS using LOCF is reported, Baseline and up to 96 weeks",,Theracos,,ALL,"ADULT, OLDER_ADULT",PHASE2,288,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",THR-1442-C-418,2011-12,2013-11,2013-12,2011-06-21,2021-05-21,2021-07-01,"Site 5, Buena Park, California, United States|Site 4, Los Angeles, California, United States|Site 3, Santa Ana, California, United States|Site 1, Hialeah, Florida, United States|Site 9, Berlin, New Jersey, United States|Site 7, Cary, North Carolina, United States|Site 6, Marion, Ohio, United States|Site 8, Munroe Falls, Ohio, United States|Site 2, Portland, Oregon, United States|Site 11, North Richland Hills, Texas, United States|Site 7, San Antonio, Texas, United States","Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/44/NCT01377844/Prot_000.pdf|Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/44/NCT01377844/SAP_001.pdf"
NCT02756832,An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2,https://clinicaltrials.gov/study/NCT02756832,,COMPLETED,The purpose of this study is to evaluate the effect of alogliptin benzoate (VIPIDIA®) on glycosylated hemoglobin (HbA1c) level dynamics in participants with diabetes mellitus type 2 (T2DM) at Month 6.,YES,Diabetes Mellitus,DRUG: Alogliptin Benzoate,"Change From Baseline in Glycosylated Hemoglobin (HbA1c) Level at Month 6, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is ≥6.5%. A negative change from Baseline indicates improvement., Baseline and Month 6","Change From Baseline in HbA1c Level at Month 6 in Subgroups of Participants With Different Clinical Characteristics, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is ≥6.5%. Subgroups included participants with different baseline clinical characteristics with predictors such as prior therapy of diabetes mellitus, sex, age group, cardiovascular risk group, therapy type (monotherapy or combined therapy), baseline body mass index (BMI) and initial glycemic control and T2DM duration. A negative change from Baseline indicates improvement., Baseline and Month 6|Percentage of Participants With a Decrease in HbA1c Level by <7.0% at Month 6, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Percentage of participants with a decrease of \<7.0% from baseline in HbA1c were reported., Baseline and Month 6|Change From Baseline in HbA1c Level Over Time, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Months 3 and 6 relative to baseline. Glycosylated hemoglobin (HbA1c) as a diagnostic criteria of diabetes mellitus is ≥6.5%. A negative change from Baseline indicates improvement., Baseline, Months 3 and 6|Percentage of Participants With Marked Hyperglycemia at Month 3, Marked hyperglycemia is defined as fasting plasma glucose (FPG) higher than or equal to 11 mmol/L., Month 3|Change From Baseline in Fasting Plasma Glucose (FPG) Levels Over Time, The change in the value of fasting plasma glucose value collected at Months 3 and 6 relative to baseline. Target FPG depended on the defined individual targets of glycemic control by HbA1c level ≤6.5 to 8.0 mmol/l. A negative change from Baseline indicates improvement., Baseline, Months 3 and 6|Change From Baseline in Weight Over Time, Change in the participant's weight was collected at Months 3 and 6 relative to baseline., Baseline, Months 3 and 6|Change From Baseline in Postprandial Glycemia Over Time, The change between the baseline (pre-prandial (before meal)) and postprandial (after meal) glucose values were collected at Months 3 and 6 relative to baseline., Baseline, Months 3 and 6|Change From Baseline in Total Cholesterol, Triglycerides, Low Density Lipoproteins and High Density Lipoproteins Over Time, The change between the total cholesterol triglycerides, low density lipoproteins and high density lipoproteins values were collected at Months 3 and 6 relative to baseline., Baseline, Months 3 and 6|Percentage of Participants With a Decrease in HbA1c Level by ≥0.3% at Month 6, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Month 6 relative to baseline. Percentage of participants with a decrease of ≥0.3% from baseline in HbA1c were reported., Baseline and Month 6|Percentage of Participants Who Used Healthcare Resources, Healthcare resources included rate of hospitalization, emergency, emergency room visits, physician office visits, and other type of usage., Baseline up to Month 6",,Takeda,,ALL,"ADULT, OLDER_ADULT",,1409,INDUSTRY,OBSERVATIONAL,Observational Model: |Time Perspective: p,Alogliptin-4018|MACS-2015-101024,2016-09-20,2018-04-28,2018-04-28,2016-04-29,2019-04-15,2019-07-10,"First City Clinical Hospital named after E.E. Vlosevich, Arkhangelsk, 163001, Russian Federation|City polyclinic #11, Barnaul, 656019, Russian Federation|Belgorod Regional Clinical hospital named after Saint I Belgorod Regional Clinical Hospital of St. Joasaph, Belgorod, 308007, Russian Federation|LLC Medical center Lotos, Chelyabinsk, 454091, Russian Federation|Istochnik clinic, Chelyabinsk, 454100, Russian Federation|Regional clinical hospital #3, Chelyabinsk, 454138, Russian Federation|Medical center Health Academy, Chita, 672038, Russian Federation|Chita State Medical Academy, Chita, 672090, Russian Federation|Ural State Medical Academy, Ekaterinburg, 620043, Russian Federation|City polyclinic #11, Kazan, 420039, Russian Federation|Ciry polyclinic #10, Kazan, 420066, Russian Federation|Kemerovo Regional Clinical Hospital named after S.V. Belyaev, Kemerovo, 650066, Russian Federation|Medical Center Clinic of Hormonal Health, Khabarovsk, 680000, Russian Federation|Regional Clinical hospital named after S.I. Sergeev, Khabarovsk, 680009, Russian Federation|Road Clinical Hospital at Khabarovsk Station - 1, Khabarovsk, 68022, Russian Federation|Northern Clinical Emergency Hospital, Kirov, 610011, Russian Federation|Kirov Clinical Hospital #7 named after V.I. Yurlova, Kirov, 610030, Russian Federation|Kostroma City hospital, Kostroma, 156005, Russian Federation|Kursk Regional Clinical Hospital, Kursk, 305007, Russian Federation|Lobnya Central City Hospital, Lobnya, 141730, Russian Federation|City polyclinic #166, Moscow, 115551, Russian Federation|Endocrinology Research Center, Moscow, 117036, Russian Federation|City polyclinic #22, Moscow, 117218, Russian Federation|City polyclinic #52, Moscow, 117546, Russian Federation|The Scientific Center of Cardiovascular Surgery named after A.N. Bakulev, Moscow, 121552, Russian Federation|CJSC Medsi, Moscow, 123056, Russian Federation|Diagnostical Center #5, Moscow, 127543, Russian Federation|Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, 199435, Russian Federation|Clinical Diagnostical Center, Nizhniy Novgorod, 603006, Russian Federation|City polyclinic #3, Nizhniy Novgorod, 603155, Russian Federation|Medical Center Healthy family LLC, Novosibirsk, 630099, Russian Federation|Republican Hospital named after V.A.Baranov, Petrozavodsk, 185000, Russian Federation|Rostov State Medical University, Rostov-on-Don, 344022, Russian Federation|City Clinical hospital #11, Ryazan, 390037, Russian Federation|City policlinic #117, Saint-Petersburg, 125167, Russian Federation|City polyclinic #109, Saint-Petersburg, 192289, Russian Federation|Saint-Petersburg Territorial Diabetological Center, Saint-Petersburg, 194354, Russian Federation|City policlinic #86, Saint-Petersburg, 195299, Russian Federation|Consultative and diagnostic polyclinic 1 of Primorsky district, Saint-Petersburg, 197183, Russian Federation|Samara Regional Clinical Diagnostical polyclinic #14, Samara, 443011, Russian Federation|LLC Center Diabet, Samara, 443041, Russian Federation|City policlinic #9, Samara, 443110, Russian Federation|City polyclinic #22, Saratov, 410005, Russian Federation|City policlinic #3, Tomsk, 634009, Russian Federation|LLC Medical center Ideale, Tomsk, 634009, Russian Federation|City policlinic #3, Tomsk, 634024, Russian Federation|Tomsk Regional Clinical Hospital, Tomsk, 634063, Russian Federation|City polyclinic #43, Ufa, 450099, Russian Federation|Regional Clinical Hospital, Vladimir, 600023, Russian Federation|Regional Clinical Hospital #1, Volgograd, 400081, Russian Federation|Volgograd State Medical University, Volgograd, 400131, Russian Federation|LLC Zdorovye, Diabetes Center, Vologda, 160019, Russian Federation|Voronezh Regional Clinical Diagnostical center, Voronezh, 394018, Russian Federation","Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/32/NCT02756832/SAP_000.pdf|Study Protocol, https://storage.googleapis.com/ctgov2-large-docs/32/NCT02756832/Prot_001.pdf"
NCT00286494,Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00286494,,COMPLETED,"The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus",YES,Diabetes Mellitus,DRUG: Alogliptin and pioglitazone|DRUG: Alogliptin and pioglitazone|DRUG: Pioglitazone,"Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26., The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline., Baseline and Week 26.","Change From Baseline in Glycosylated Hemoglobin (Week 4)., The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and Glycosylated Hemoglobin collected at baseline., Baseline and Week 4.|Change From Baseline in Glycosylated Hemoglobin (Week 8)., The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and Glycosylated Hemoglobin collected at baseline., Baseline and Week 8.|Change From Baseline in Glycosylated Hemoglobin (Week 12)., The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and Glycosylated Hemoglobin collected at baseline., Baseline and Week 12.|Change From Baseline in Glycosylated Hemoglobin (Week 16)., The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and Glycosylated Hemoglobin collected at baseline., Baseline and Week 16.|Change From Baseline in Glycosylated Hemoglobin (Week 20)., The change in the value of Glycosylated Hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and Glycosylated Hemoglobin collected at baseline., Baseline and Week 20.|Change From Baseline in Fasting Plasma Glucose (Week 1)., The change between the value of fasting plasma glucose collected at final visit or week 1 and fasting plasma glucose collected at baseline., Baseline and Week 1.|Change From Baseline in Fasting Plasma Glucose (Week 2)., The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline., Baseline and Week 2.|Change From Baseline in Fasting Plasma Glucose (Week 4)., The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline., Baseline and Week 4.|Change From Baseline in Fasting Plasma Glucose (Week 8)., The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline., Baseline and Week 8.|Change From Baseline in Fasting Plasma Glucose (Week 12)., The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline., Baseline and Week 12.|Change From Baseline in Fasting Plasma Glucose (Week 16)., The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline., Baseline and Week 16.|Change From Baseline in Fasting Plasma Glucose (Week 20)., The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline., Baseline and Week 20.|Change From Baseline in Fasting Plasma Glucose (Week 26)., The change between the value of fasting plasma glucose collected at week 26 or final visit and fasting plasma glucose collected at baseline., Baseline and Week 26.|Number of Participants With Marked Hyperglycemia (Fasting Plasma Glucose ≥ 200 mg Per dL)., The number of participants with a fasting plasma glucose value greater than or equal to 200 mg per dL during the 26 week study., 26 Weeks.|Number of Participants Requiring Rescue., The number of participants requiring rescue for failing to achieve pre-specified glycemic targets during the 26 week study., 26 Weeks.|Change From Baseline in Fasting Proinsulin (Week 4)., The change between the value of fasting proinsulin collected at week 4 and fasting proinsulin collected at baseline., Baseline and Week 4.|Change From Baseline in Fasting Proinsulin (Week 8)., The change between the value of fasting proinsulin collected at week 8 and fasting proinsulin collected at baseline., Baseline and Week 8.|Change From Baseline in Fasting Proinsulin (Week 12)., The change between the value of fasting proinsulin collected at week 12 and fasting proinsulin collected at baseline., Baseline and Week 12.|Change From Baseline in Fasting Proinsulin (Week 16)., The change between the value of fasting proinsulin collected at week 16 and fasting proinsulin collected at baseline., Baseline and Week 16.|Change From Baseline in Fasting Proinsulin (Week 20)., The change between the value of fasting proinsulin collected at week 20 and fasting proinsulin collected at baseline., Baseline and Week 20.|Change From Baseline in Fasting Proinsulin (Week 26)., The change between the value of fasting proinsulin collected at week 26 or final visit and fasting proinsulin collected at baseline., Baseline and Week 26.|Change From Baseline in Insulin (Week 4)., The change between the value of insulin collected at week 4 and insulin collected at baseline., Baseline and Week 4.|Change From Baseline in Insulin (Week 8)., The change between the value of insulin collected at week 8 and insulin collected at baseline., Baseline and Week 8.|Change From Baseline in Insulin (Week 12)., The change between the value of insulin collected at week 12 and insulin collected at baseline., Baseline and Week 12.|Change From Baseline in Insulin (Week 16)., The change between the value of insulin collected at week 16 and insulin collected at baseline., Baseline and Week 16.|Change From Baseline in Insulin (Week 20)., The change between the value of insulin collected at week 20 and insulin collected at baseline., Baseline and Week 20.|Change From Baseline in Insulin (Week 26)., The change between the value of insulin collected at week 26 and insulin collected at baseline., Baseline and Week 26.|Change From Baseline in Proinsulin/Insulin Ratio (Week 4)., The change between the ratio value of proinsulin and insulin collected at week 4 and the ratio value of proinsulin and insulin collected at baseline., Baseline and Week 4.|Change From Baseline in Proinsulin/Insulin Ratio (Week 8)., The change between the ratio value of proinsulin and insulin collected at week 8 and the ratio value of proinsulin and insulin collected at baseline., Baseline and Week 8.|Change From Baseline in Proinsulin/Insulin Ratio (Week 12)., The change between the ratio value of proinsulin and insulin collected at week 12 and the ratio value of proinsulin and insulin collected at baseline., Baseline and Week 12.|Change From Baseline in Proinsulin/Insulin Ratio (Week 16)., The change between the ratio value of proinsulin and insulin collected at week 16 and the ratio value of proinsulin and insulin collected at baseline., Baseline and Week 16.|Change From Baseline in Proinsulin/Insulin Ratio (Week 20)., The change between the ratio value of proinsulin and insulin collected at week 20 and the ratio value of proinsulin and insulin collected at baseline., Baseline and Week 20.|Change From Baseline in Proinsulin/Insulin Ratio (Week 26)., The change between the ratio value of proinsulin and insulin collected at week 26 or final visit and the ratio value of proinsulin and insulin collected at baseline., Baseline and Week 26.|Change From Baseline in C-peptide (Week 4)., The change between the value of C-peptide collected at week 4 and C-peptide collected at baseline., Baseline and Week 4.|Change From Baseline in C-peptide (Week 8)., The change between the value of C-peptide collected at week 8 and C-peptide collected at baseline., Baseline and Week 8.|Change From Baseline in C-peptide (Week 12)., The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline., Baseline and Week 12.|Change From Baseline in C-peptide (Week 16)., The change between the value of C-peptide collected at week 16 and C-peptide collected at baseline., Baseline and Week 16.|Change From Baseline in C-peptide (Week 20)., The change between the value of C-peptide collected at week 20 and C-peptide collected at baseline., Baseline and Week 20.|Change From Baseline in C-peptide (Week 26)., The change between the value of C-peptide collected at week 26 or final visit and C-peptide collected at baseline., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin ≤ 6.5%., The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 6.5% during the 26 week study., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin ≤ 7.0%., The number of participants with a value for the percentage of glycosylated hemoglobin less (the percentage of hemoglobin that is bound to glucose) than or equal to 7.0% during the 26 week study., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin ≤ 7.5%., The number of participants with a value for the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) less than or equal to 7.5% during the 26 week study., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 0.5%., The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 0.5% during the 26 week study., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.0%., The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.0% during the 26 week study., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 1.5%., The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 1.5% during the 26 week study., Baseline and Week 26.|Number of Participants With Glycosylated Hemoglobin Decrease From Baseline ≥ 2.0%., The number of participants with a decrease from baseline in the percentage of glycosylated hemoglobin (the percentage of hemoglobin that is bound to glucose) greater than or equal to 2.0% during the 26 week study., Baseline and Week 26.|Change From Baseline in Body Weight (Week 8)., The change between Body Weight measured at week 8 and Body Weight measured at baseline., Baseline and Week 8.|Change From Baseline in Body Weight (Week 12)., The change between Body Weight measured at week 12 and Body Weight measured at baseline., Baseline and Week 12.|Change From Baseline in Body Weight (Week 20)., The change between Body Weight measured at week 20 and Body Weight measured at baseline., Baseline and Week 20.|Change From Baseline in Body Weight (Week 26)., The change between Body Weight measured at week 26 or final visit and Body Weight measured at baseline., Baseline and Week 26.",,Takeda,,ALL,"ADULT, OLDER_ADULT",PHASE3,493,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",SYR-322-TZD-009|2005-004669-40|U1111-1113-8552,2006-02,2007-08,2007-08,2006-02-03,2011-06-08,2012-02-03,"Birmingham, Alabama, United States|Phoenix, Arizona, United States|Anaheim, California, United States|Artesia, California, United States|Fresno, California, United States|Mission Viejo, California, United States|Northridge, California, United States|Orange, California, United States|San Diego, California, United States|Walnut Creek, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Norwalk, Connecticut, United States|Washington, District of Columbia, United States|Clearwater, Florida, United States|Cocoa Beach, Florida, United States|Hollywood, Florida, United States|Kissimmee, Florida, United States|Longwood, Florida, United States|New Port Richey, Florida, United States|Ocala, Florida, United States|Ocoee, Florida, United States|St. Cloud, Florida, United States|Tampa, Florida, United States|Lawrenceville, Georgia, United States|Honolulu, Hawaii, United States|Idaho Falls, Idaho, United States|Chicago, Illinois, United States|Avon, Indiana, United States|Elkhart, Indiana, United States|Evansville, Indiana, United States|Lafayette, Indiana, United States|Erlanger, Kentucky, United States|Baltimore, Maryland, United States|Sudbury, Massachusetts, United States|Chesterfield, Missouri, United States|St. Louis, Missouri, United States|Omaha, Nebraska, United States|Berlin, New Jersey, United States|Burlington, North Carolina, United States|Charlotte, North Carolina, United States|Hickory, North Carolina, United States|Morehead City, North Carolina, United States|Pinehurst, North Carolina, United States|Wilmington, North Carolina, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Dayton, Ohio, United States|Tulsa, Oklahoma, United States|Medford, Oregon, United States|Lansdale, Pennsylvania, United States|West Grove, Pennsylvania, United States|Charleston, South Carolina, United States|Columbia, South Carolina, United States|Simpsonville, South Carolina, United States|Bristol, Tennessee, United States|Cookeville, Tennessee, United States|Milan, Tennessee, United States|Corpus Christi, Texas, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Temple, Texas, United States|Texarkana, Texas, United States|Burlington, Vermont, United States|Multiple Cities, Argentina|Multiple Cities, Australia|Multiple Cities, Brazil|Multiple Cities, Czech Republic|Multiple Cities, Germany|Multiple Cities, Guatemala|Multiple Cities, Hungary|Multiple Cities, India|Multiple Cities, Mexico|Multiple Cities, Netherlands|Multiple Cities, New Zealand|Multiple Cities, Peru|Multiple Cities, South Africa",
NCT00432276,Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00432276,,COMPLETED,"The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.",YES,Diabetes Mellitus,DRUG: Alogliptin|DRUG: Pioglitazone|DRUG: Metformin|DRUG: Placebo,"Change From Baseline in Glycosylated Hemoglobin (HbA1c), The change from Baseline to Week 26 and Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound)., Baseline and Weeks 26 and 52.","Change From Baseline in HbA1c Over Time, The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) during the study. Least Squares Means were from an Analysis of Covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and baseline metformin dose and baseline HbA1c as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 34 and 42.|Percentage of Participants With Glycosylated Hemoglobin ≤ 6.5%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with HbA1c less than or equal to 6.5%., Weeks 26 and 52.|Percentage of Participants With Glycosylated Hemoglobin ≤ 7.0%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with HbA1c less than or equal to 7%., Weeks 26 and 52.|Percentage of Participants With Glycosylated Hemoglobin ≤ 7.5%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with HbA1c less than or equal to 7.5%., Weeks 26 and 52.|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 0.5%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5%., Weeks 26 and 52.|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.0%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0%., Weeks 26 and 52.|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 1.5%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5%., Weeks 26 and 52.|Percentage of Participants With a Decrease in Glycosylated Hemoglobin ≥ 2.0%, Clinical response at Weeks 26 and 52 was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0%., Weeks 26 and 52.|Change From Baseline in Fasting Plasma Glucose, The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least Squares Means were from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline FPG as covariates., Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Percentage of Participants With Marked Hyperglycemia, Marked Hyperglycemia is defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.10 mmol/L)., Baseline to Week 52|Percentage of Participants Meeting Hyperglycemic Rescue Criteria, Rescue was defined as meeting 1 of the following criteria, confirmed by a 2nd sample drawn within 7 days after the first sample and analyzed by the central laboratory:

1. After more than 2 weeks of treatment but prior to the Week 4 Visit: A single fasting plasma glucose (FPG) ≥275 mg/dL;
2. From the Week 4 Visit but prior to the Week 8 Visit: A single FPG ≥250 mg/dL;
3. From the Week 8 Visit but prior to the Week 12 Visit: A single FPG ≥225 mg/dL;
4. From the Week 12 Visit through the End-of-Treatment Visit: HbA1c ≥8.5% AND ≤0.5% reduction in HbA1c as compared with the baseline HbA1c., Baseline to Week 52|Change From Baseline in Fasting Proinsulin, Proinsulin is a precursor to insulin, and was measured as an indicator of pancreatic function. The change from Baseline in fasting proinsulin was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least Squares Means were from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline fasting proinsulin as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in Fasting Insulin, The change from Baseline in fasting insulin was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least Squares Means were from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline fasting insulin as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in Proinsulin/Insulin Ratio, The ratio of proinsulin to insulin was calculated as proinsulin (pmol/L) / insulin (μIU/mL) at weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52 relative to the Baseline value. Least squares means were from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline fasting proinsulin/insulin ratio as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in C-peptide, C-peptide is a byproduct created when the hormone insulin is produced and is measured by a blood test. Change from Baseline was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline fasting C-peptide as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in Calculated HOMA Insulin Resistance, The Homeostasis Model Assessment of insulin resistance (HOMA IR) measures insulin resistance based on fasting glucose and insulin measurements:

HOMA IR = fasting plasma insulin (µIU/mL) \* fasting plasma glucose (mmol/L) / 22.5

A higher number indicates a greater degree of insulin resistance. The change from Baseline in HOMA IR was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline HOMA insulin resistance as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Calculated HOMA Beta-cell Function, The Homeostasis Model Assessment (HOMA) estimates steady state beta cell function (%B) as a percentage of a normal reference population.

HOMA %B = 20 \* insulin (µIU/mL) / fasting plasma glucose (mmol/L) - 3.5

The change from Baseline in the homeostasis model assessment of beta cell function was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline HOMA beta cell function as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Body Weight, Change from Baseline in body weight was assessed at Weeks 4, 8, 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline body weight as covariates., Baseline and Weeks 4, 8, 12, 26, 42 and 52.|Change From Baseline in Total Cholesterol, Change from Baseline in total cholesterol was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline total cholesterol as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in High-Density Lipoprotein Cholesterol, Change from Baseline in high-density lipoprotein cholesterol (HDL-C) was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline HDL cholesterol as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in Low-Density Lipoprotein Cholesterol, Change from Baseline in low-density lipoprotein cholesterol (LDL-C) was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline LDL cholesterol as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in Triglycerides, Change from Baseline in triglycerides was assessed at Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline triglycerides as covariates., Baseline and Weeks 4, 8, 12, 16, 20, 26, 34, 42 and 52.|Change From Baseline in Free Fatty Acids, Change from Baseline in free fatty acids was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline free fatty acids as covariates., Baseline and Weeks 12, 26, 42, and 52.|Change From Baseline in Apolipoprotein A1, Change from Baseline in Apolipoprotein A1 was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A1 as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Apolipoprotein A2, Change from Baseline in Apolipoprotein A2 was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein A2 as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Apolipoprotein B, Change from Baseline in Apolipoprotein B was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein B as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Apolipoprotein C-III, Change from Baseline in Apolipoprotein C-III was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline apolipoprotein C-III as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Plasminogen Activator Inhibitor-1, Change from Baseline in plasminogen activator inhibitor-1 (PAI-1) was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline PAI-1 as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in High-sensitivity C-Reactive Protein, Change from Baseline in high-sensitivity C-Reactive Protein (hsCRP) was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline hsCRP as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Adiponectin, Change from Baseline in adiponectin was assessed at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline adiponectin as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Nuclear Magnetic Resonance Lipid Fractionation Total Triglycerides, Nuclear Magnetic Resonance (NMR) lipid fractionation was used to assess the change from Baseline in total triglyceride levels at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline NMR triglycerides as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Very Low Density Lipoprotein (VLDL) / Chylomicron Particles, The change from Baseline in levels of total VLDL/chylomicron particles and large VLDL/chylomicron particles was assessed by NMR lipid fractionation at Weeks 12, 26, 42 and 52.

Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline VLDL/chylomicron particles as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in VLDL / Chylomicron Triglycerides, The change from Baseline in levels of VLDL/chylomicron triglycerides was assessed by NMR lipid fractionation at Weeks 12, 26, 42 and 52.

Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline VLDL/chylomicron triglycerides as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in VLDL Particles, The change from Baseline in levels of medium VLDL particles and small VLDL particles was assessed by NMR fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline VLDL particles as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Mean VLDL Particle Size, Change from Baseline in mean VLDL particle size was assessed by NMR lipid fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline mean VLDL particle size as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Intermediate Density Lipoprotein (IDL) Particles, The change from Baseline in levels of IDL particles was assessed by NMR lipid fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline IDL particles as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Low Density Lipoprotein (LDL) Particles, The change from Baseline in levels of total, large, medium-small, total small and very small LDL particles was assessed by NMR fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline LDL particles as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Mean LDL Particle Size, Change from Baseline in mean LDL particle size was assessed by NMR lipid fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline mean LDL particle size as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in High Density Lipoprotein (HDL) Particles, The change from Baseline in levels of total, large, medium and small HDL particles was assessed by NMR fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline HDL particles as covariates., Baseline and Weeks 12, 26, 42 and 52.|Change From Baseline in Mean HDL Particle Size, Change from Baseline in mean HDL particle size was assessed by NMR lipid fractionation at Weeks 12, 26, 42 and 52. Least squares means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and baseline metformin dose and baseline mean HDL particle size as covariates., Baseline and Weeks 12, 26, 42 and 52.",,Takeda,,ALL,"ADULT, OLDER_ADULT",PHASE3,803,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",01-06-TL-322OPI-004|2006-006025-73|U1111-1112-3363,2007-01,2009-05,2009-06,2007-02-07,2013-02-19,2013-04-04,"Birmingham, Alabama, United States|Huntsville, Alabama, United States|Lake Havasu City, Arizona, United States|Little Rock, Arkansas, United States|Foothill Ranch, California, United States|Los Alamitos, California, United States|Los Angeles, California, United States|Pismo Beach, California, United States|San Diego, California, United States|Golden, Colorado, United States|Clearwater, Florida, United States|Hialeah, Florida, United States|Lakeland, Florida, United States|Marianna, Florida, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|Pembroke Pines, Florida, United States|Sebastian, Florida, United States|South Miami, Florida, United States|Tampa, Florida, United States|Winter Park, Florida, United States|Blue Ridge, Georgia, United States|Conyers, Georgia, United States|Decatur, Georgia, United States|Duluth, Georgia, United States|Dunwoody, Georgia, United States|Warner Robins, Georgia, United States|Boise, Idaho, United States|Coeur D'Alene, Idaho, United States|Burr Ridge, Illinois, United States|Chicago, Illinois, United States|Melrose Park, Illinois, United States|Naperville, Illinois, United States|O'Fallon, Illinois, United States|Bloomington, Indiana, United States|Mishawaka, Indiana, United States|Overland Park, Kansas, United States|Marrero, Louisiana, United States|Elkton, Maryland, United States|Rockville, Maryland, United States|Towson, Maryland, United States|Marlborough, Massachusetts, United States|Bay City, Michigan, United States|St. Clair Shores, Michigan, United States|McCook, Nebraska, United States|Las Vegas, Nevada, United States|Blackwood, New Jersey, United States|Trenton, New Jersey, United States|West Caldwell, New Jersey, United States|Asheboro, North Carolina, United States|Charlotte, North Carolina, United States|Mooresville, North Carolina, United States|Shelby, North Carolina, United States|Sparta, North Carolina, United States|Bismarck, North Dakota, United States|Orrville, Ohio, United States|Norman, Oklahoma, United States|Ashland, Oregon, United States|Aliquippa, Pennsylvania, United States|Altoona, Pennsylvania, United States|Dawningtown, Pennsylvania, United States|Fleetwood, Pennsylvania, United States|Kingston, Pennsylvania, United States|Norristown, Pennsylvania, United States|Pittsburgh, Pennsylvania, United States|Tipton, Pennsylvania, United States|Florence, South Carolina, United States|Taylors, South Carolina, United States|Williamston, South Carolina, United States|Watertown, South Dakota, United States|Kingsport, Tennessee, United States|Milan, Tennessee, United States|Nashville, Tennessee, United States|Arlington, Texas, United States|Austin, Texas, United States|Colleyville, Texas, United States|El Paso, Texas, United States|Garland, Texas, United States|Houston, Texas, United States|Hurst, Texas, United States|San Antonio, Texas, United States|Seguin, Texas, United States|Hampton, Virginia, United States|Norfolk, Virginia, United States|Richmond, Virginia, United States|Virginia Beach, Virginia, United States",
